123 related articles for article (PubMed ID: 12195123)
1. Effect of YM471, an orally active non-peptide arginine vasopressin receptor antagonist, on human vascular smooth muscle cells.
Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Yatsu T; Uchida W; Taniguchi N; Tanaka A
J Hypertens; 2002 Sep; 20(9):1807-14. PubMed ID: 12195123
[TBL] [Abstract][Full Text] [Related]
2. Effect of YM471, a nonpeptide AVP receptor antagonist, on human coronary artery smooth muscle cells.
Tahara A; Tsukada J; Tomura Y; Wada K; Kusayama T; Ishii N; Yatsu T; Uchida W; Taniguchi N; Tanaka A
Peptides; 2002 Oct; 23(10):1809-16. PubMed ID: 12383869
[TBL] [Abstract][Full Text] [Related]
3. Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
Tsukada J; Tahara A; Tomura Y; Wada Ki ; Kusayama T; Ishii N; Yatsu T; Uchida W; Taniguchi N; Tanaka A
Br J Pharmacol; 2001 Jul; 133(5):746-54. PubMed ID: 11429400
[TBL] [Abstract][Full Text] [Related]
4. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells.
Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
J Cardiovasc Pharmacol; 1997 Dec; 30(6):759-66. PubMed ID: 9436815
[TBL] [Abstract][Full Text] [Related]
5. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.
Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Cardiovasc Res; 1998 Apr; 38(1):198-205. PubMed ID: 9683922
[TBL] [Abstract][Full Text] [Related]
6. Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.
Serradeil-Le Gal C; Herbert JM; Delisee C; Schaeffer P; Raufaste D; Garcia C; Dol F; Marty E; Maffrand JP; Le Fur G
Am J Physiol; 1995 Jan; 268(1 Pt 2):H404-10. PubMed ID: 7840290
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin stimulates Ca2+ spiking activity in A7r5 vascular smooth muscle cells via activation of phospholipase A2.
Byron KL
Circ Res; 1996 May; 78(5):813-20. PubMed ID: 8620601
[TBL] [Abstract][Full Text] [Related]
9. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
[TBL] [Abstract][Full Text] [Related]
10. Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells.
Serradeil-Le Gal C; Bourrié B; Raufaste D; Carayon P; Garcia C; Maffrand JP; Le Fur G; Casellas P
Biochem Pharmacol; 1994 Feb; 47(4):633-41. PubMed ID: 8129742
[TBL] [Abstract][Full Text] [Related]
11. Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy.
Tahara A; Tsukada J; Tomura Y; Suzuki T; Yatsu T; Shibasaki M
Vascul Pharmacol; 2007 Jun; 46(6):463-9. PubMed ID: 17395547
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist.
Tsukada J; Tahara A; Tomura Y; Wada Ki; Kusayama T; Ishii N; Aoki M; Yatsu T; Uchida W; Taniguchi N; Tanaka A
Eur J Pharmacol; 2002 Jun; 446(1-3):129-38. PubMed ID: 12098594
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of vasopressin action in vascular smooth muscle by the V1 antagonist OPC-21268.
Li X; Kribben A; Wieder ED; Tsai P; Nemenoff RA; Schrier RW
Hypertension; 1994 Feb; 23(2):217-22. PubMed ID: 8307632
[TBL] [Abstract][Full Text] [Related]
14. Vasopressin V
Zhang L; Wang X; Cao H; Chen Y; Chen X; Zhao X; Xu F; Wang Y; Woo AY; Zhu W
Eur J Pharmacol; 2016 Dec; 792():15-25. PubMed ID: 27773680
[TBL] [Abstract][Full Text] [Related]
15. Distinct inhibition by non-peptide and peptide arginine vasopressin antagonists of vasopressin-induced activation of mitogen-activated protein kinase in cultured rat vascular smooth muscle cells.
Okada K; Sasaki R; Ishikawa S; Saito T
Biochem Biophys Res Commun; 1994 Apr; 200(2):1155-60. PubMed ID: 8179597
[TBL] [Abstract][Full Text] [Related]
16. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.
Hiroyama M; Wang S; Aoyagi T; Oikawa R; Sanbe A; Takeo S; Tanoue A
Eur J Pharmacol; 2007 Mar; 559(2-3):89-97. PubMed ID: 17275806
[TBL] [Abstract][Full Text] [Related]
17. Arginine vasopressin inhibits interleukin-1 beta-stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells.
Kusano E; Tian S; Umino T; Tetsuka T; Ando Y; Asano Y
J Hypertens; 1997 Jun; 15(6):627-32. PubMed ID: 9218182
[TBL] [Abstract][Full Text] [Related]
18. Arginine vasopressin and oxytocin increase intracellular calcium and cAMP in human glomerular epithelial cells in culture.
Späth M; Pavenstädt H; Petersen J; Schollmeyer P
Kidney Blood Press Res; 1996; 19(2):81-6. PubMed ID: 8871886
[TBL] [Abstract][Full Text] [Related]
19. Binding and signal transduction characteristics of the nonpeptide vasopressin V1A receptor-selective antagonist YM218 in cultured rat mesangial cells.
Tahara A; Tsukada J; Tomura Y; Kusayama T; Momose K; Taniguchi N; Suzuki T; Yatsu T; Shibasaki M
Pharmacology; 2006; 78(2):81-90. PubMed ID: 16966841
[TBL] [Abstract][Full Text] [Related]
20. Human internal mammary artery responses to non-peptide vasopressin antagonists.
Liu JJ; Phillips PA; Burrell LM; Buxton BB; Johnston CI
Clin Exp Pharmacol Physiol; 1994 Feb; 21(2):121-4. PubMed ID: 8039263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
